1 Coppola A, "Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies" 16 (16): 13-19, 2010
2 Plug I, "Thirty years of hemophilia treatment in the Netherlands, 1972-2001" 104 : 3494-3500, 2004
3 Franchini M, "The management of hemophilia in elderly patients" 2 : 361-368, 2007
4 Mannucci PM, "The hemophilias--from royal genes to gene therapy" 344 : 1773-1779, 2001
5 Wight J, "The epidemiology of inhibitors in haemophilia A: a systematic review" 9 : 418-435, 2003
6 "Statistics of HIV/AIDS 1984-2007/12/31"
7 "Statistics of HIV/AIDS 1984-2003/1/31"
8 Plug I, "Social participation of patients with hemophilia in the Netherlands" 111 : 1811-1815, 2008
9 Liou WS, "Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan" 17 : 45-54, 2011
10 Carcao MD, "Round Table Group. Prophylaxis in the haemophilia population-optimizing therapy" 13 : 227-232, 2007
1 Coppola A, "Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies" 16 (16): 13-19, 2010
2 Plug I, "Thirty years of hemophilia treatment in the Netherlands, 1972-2001" 104 : 3494-3500, 2004
3 Franchini M, "The management of hemophilia in elderly patients" 2 : 361-368, 2007
4 Mannucci PM, "The hemophilias--from royal genes to gene therapy" 344 : 1773-1779, 2001
5 Wight J, "The epidemiology of inhibitors in haemophilia A: a systematic review" 9 : 418-435, 2003
6 "Statistics of HIV/AIDS 1984-2007/12/31"
7 "Statistics of HIV/AIDS 1984-2003/1/31"
8 Plug I, "Social participation of patients with hemophilia in the Netherlands" 111 : 1811-1815, 2008
9 Liou WS, "Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan" 17 : 45-54, 2011
10 Carcao MD, "Round Table Group. Prophylaxis in the haemophilia population-optimizing therapy" 13 : 227-232, 2007
11 Chan V, "Restriction fragment length polymorphisms associated with factor VIII: C gene in Chinese" 79 : 128-131, 1988
12 Ettingshausen CE, "Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development" 12 (12): 102-106, 2006
13 Gouw SC, "Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study" 109 : 4693-4697, 2007
14 Coppola A, "Prophylaxis in people with haemophilia" 101 : 674-681, 2009
15 Fischer K, "Prophylaxis for severe haemophilia: clinical and economical issues" 9 : 376-381, 2003
16 Geraghty S, "Practice patterns in haemophilia A therapy -- global progress towards optimal care" 12 : 75-81, 2006
17 "Population by age"
18 Soucie JM, "Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators" 59 : 288-294, 1998
19 "National Health Insurance in Taiwan 2011 Annual Report"
20 Darby SC, "Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV" 110 : 815-825, 2007
21 Plug I, "Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study" 4 : 510-516, 2006
22 Tagliaferri A, "Mortality and causes of death in Italian persons with haemophilia, 1990-2007" 16 : 437-446, 2010
23 Berntorp E, "Modern treatment of haemophilia" 73 : 691-701, 1995
24 Mejia-Carvajal C, "Life expectancy in hemophilia outcome" 4 : 507-509, 2006
25 Goudemand J, "Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A" 107 : 46-51, 2006
26 Street A, "Haemophilia and ageing" 12 (12): 8-12, 2006
27 "Guidelines for the management of hemophilia"
28 Chen YC, "Genetic analysis of haemophilia A in Taiwan" 16 : 538-544, 2010
29 Smith PS, "Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis" 129 : 424-431, 1996
30 Chalmers EA, "Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A" 13 : 149-155, 2007
31 Carlsson KS, "Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden" 10 : 515-526, 2004
32 Heemstra HE, "Cost of severe haemophilia in Toronto" 11 : 254-260, 2005
33 Ling SC, "Children and Adolescents with Haemophilia in Hong Kong: an Epidemiological and Clinical Review" 11 : 13-19, 2006
34 "Cherishing health insurance for a healthy Taiwan 2006"
35 "Causes of death statistics"
36 "Cases of HIV/AIDS by exposure category"
37 Hemophilia A, "Canadian Hemophilia registry-Factor VIII"
38 Hemophilia B, "Canadian Hemophilia registry-Factor IX"
39 Iorio A, "Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis" 14 : 444-453, 2008
40 Ono O, "Assessment of haemophilia treatment practice pattern in Japan" 15 : 1032-1038, 2009
41 "Annual Report 2009. United Kingdom Haemophilia Centre Doctors’ Organisation 2009"
42 Ahmad OB, "Age Standardization of rates: a new WHO standard"
43 Stonebraker JS, "A study of variations in the reported hemophilia B prevalence around the world"
44 Stonebraker JS, "A study of variations in the reported haemophilia A prevalence around the world" 16 : 20-32, 2010
45 Stonebraker JS, "A study of reported factor VIII use around the world" 16 : 33-46, 2010
46 StataCorp LP, "4905 Lakeway Drive College Station"